Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Treatment with a chimeric mAb to TNF-alpha has been shown to suppress inflammation and improve patient well-being in rheumatoid arthritis (RA), but the mechanisms of action of such treatment have not been fully explored. Here we show that in vivo administration of anti-TNF-alpha Ab, using a longitudinal analysis, results in the rapid down-regulation of a spectrum of cytokines, cytokine inhibitors, and acute-phase proteins. Marked diurnal variation in the serum levels of some of these were detected. These results were consistent with the concept of a cytokine-dependent cytokine cascade, and the degree of clinical benefit noted after anti-TNF-alpha therapy is probably due to the reduction in many proinflammatory mediators apart from TNF-alpha, such as IL-6, which reached normal levels within 24 h. Serum levels of cytokine inhibitors such as soluble p75 and p55 TNFR were reduced as was IL-1 receptor antagonist. Reductions in acute-phase proteins occurred after serum IL-6 fell and included serum amyloid A, haptoglobin, and fibrinogen. The latter reduction could be of importance, as it is a risk factor for atherosclerosis, which is augmented in RA patients.

Type

Journal article

Journal

Journal of immunology (Baltimore, Md. : 1950)

Publication Date

08/1999

Volume

163

Pages

1521 - 1528

Addresses

Department of Rheumatology, Charing Cross Hospital, London, United Kingdom.

Keywords

Humans, Arthritis, Rheumatoid, Sialoglycoproteins, Tumor Necrosis Factor-alpha, Acute-Phase Proteins, Receptors, Tumor Necrosis Factor, Antirheumatic Agents, Interleukin-1, Interleukin-6, Antibodies, Monoclonal, Cytokines, Longitudinal Studies, Double-Blind Method, Solubility, Interleukin 1 Receptor Antagonist Protein